Atlas Trials

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

Clinical trial NCT05920018 · UNKNOWN

Trial details

NCT number
NCT05920018
Sponsor
Universität Münster
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing-Remitting
Start date
2023-10-02
Primary completion
2025-02-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.